2015 Symposium: Scale Up to Get Down to Zero TB Deaths, New Infections, and Suffering
On December 4, 2015, in Cape Town, South Africa, Treatment Action Group, Harvard Medical School, Partners In Health, Treatment Action Campaign, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference in Barcelona. The symposium,…
An Activist’s Guide to Regulatory Issues: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment
Tuberculosis Research Funding Crisis Imperils Elimination Goal
2015 Report on TB Research Funding Trends
The FDA’s Concession Conundrum
Can regulatory incentives promote responsible TB drug development? By Lindsay McKenna and Erica Lessem There are woefully few drugs in development with the potential to improve the safety and effectiveness of tuberculosis (TB) treatment. Indeed, the market-driven approach to drug…
Improving Regulatory Systems to Address Global TB Drug Access Failures
Worldwide inefficiencies in drug approval processes are proving disastrous for people living with TB and other diseases By Erica Lessem Access to safe and effective tuberculosis (TB) medicines depends greatly on efficient and stringent regulatory review, without which improved health…
TAGline Fall 2015
2015 Pipeline Report
TB R&D’s Shift to the Left
As the Bill & Melinda Gates Foundation realigns its TB vaccine strategy to focus on early-stage candidate development, equitable access priorities must also be established before large-scale trials are conducted By Mike Frick The Bill & Melinda Gates Foundation has…